Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

171 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
VEGF-targeted therapy: mechanisms of anti-tumour activity.
Ellis LM, Hicklin DJ. Ellis LM, et al. Among authors: hicklin dj. Nat Rev Cancer. 2008 Aug;8(8):579-91. doi: 10.1038/nrc2403. Epub 2008 Jul 3. Nat Rev Cancer. 2008. PMID: 18596824 Review.
Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology.
Ellis LM, Hicklin DJ. Ellis LM, et al. Among authors: hicklin dj. Clin Cancer Res. 2009 Dec 15;15(24):7471-7478. doi: 10.1158/1078-0432.CCR-09-1070. Clin Cancer Res. 2009. PMID: 20008847 Free article.
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.
Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D. Kaplan RN, et al. Nature. 2005 Dec 8;438(7069):820-7. doi: 10.1038/nature04186. Nature. 2005. PMID: 16341007 Free PMC article.
Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.
Laakkonen P, Waltari M, Holopainen T, Takahashi T, Pytowski B, Steiner P, Hicklin D, Persaud K, Tonra JR, Witte L, Alitalo K. Laakkonen P, et al. Cancer Res. 2007 Jan 15;67(2):593-9. doi: 10.1158/0008-5472.CAN-06-3567. Cancer Res. 2007. PMID: 17234768
Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS. Viloria-Petit A, et al. Cancer Res. 2001 Jul 1;61(13):5090-101. Cancer Res. 2001. PMID: 11431346
Effect of molecular therapeutics on liver regeneration in a murine model.
Van Buren G 2nd, Yang AD, Dallas NA, Gray MJ, Lim SJ, Xia L, Fan F, Somcio R, Wu Y, Hicklin DJ, Ellis LM. Van Buren G 2nd, et al. Among authors: hicklin dj. J Clin Oncol. 2008 Apr 10;26(11):1836-42. doi: 10.1200/JCO.2007.11.6566. J Clin Oncol. 2008. PMID: 18398149
Antiangiogenic therapy--evolving view based on clinical trial results.
Jayson GC, Hicklin DJ, Ellis LM. Jayson GC, et al. Among authors: hicklin dj. Nat Rev Clin Oncol. 2012 Feb 14;9(5):297-303. doi: 10.1038/nrclinonc.2012.8. Nat Rev Clin Oncol. 2012. PMID: 22330688 Review.
Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS. Folkins C, et al. Among authors: hicklin dj. Cancer Res. 2007 Apr 15;67(8):3560-4. doi: 10.1158/0008-5472.CAN-06-4238. Cancer Res. 2007. PMID: 17440065
Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target.
Camp ER, Yang A, Gray MJ, Fan F, Hamilton SR, Evans DB, Hooper AT, Pereira DS, Hicklin DJ, Ellis LM. Camp ER, et al. Among authors: hicklin dj. Cancer. 2007 Mar 15;109(6):1030-9. doi: 10.1002/cncr.22490. Cancer. 2007. PMID: 17311308
Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.
Piloto O, Levis M, Huso D, Li Y, Li H, Wang MN, Bassi R, Balderes P, Ludwig DL, Witte L, Zhu Z, Hicklin DJ, Small D. Piloto O, et al. Among authors: hicklin dj. Cancer Res. 2005 Feb 15;65(4):1514-22. doi: 10.1158/0008-5472.CAN-04-3081. Cancer Res. 2005. PMID: 15735040
171 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page